Pfizer and Merck KGaA to Terminate LateStage Ovarian Cancer Trial

Pfizer and Merck KGaA to Terminate Late-Stage Ovarian Cancer Trial

10:26 EST 26 Dec 2018 | Pharmaceutical Processing

News
Topline results showed that the study, which is evaluating avelumab, would not achieve superiority in the primary endpoint of progression-free survival.
Contributed Author: 
Pfizer Inc.
Topics: 

Original Article: Pfizer and Merck KGaA to Terminate Late-Stage Ovarian Cancer Trial

More From BioPortfolio on "Pfizer and Merck KGaA to Terminate Late-Stage Ovarian Cancer Trial"